Quick Answer
Cogent Biosciences, Inc. reported R&D Expense of $269.78 million for fiscal year 2025.
Cogent Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $269.78M | +16.0% |
| 2024 | $232.66M | +33.9% |
| 2023 | $173.75M | +42.9% |
| 2022 | $121.63M | +117.5% |
| 2021 | $55.91M | +117.2% |
| 2020 | $25.74M | -41.1% |
| 2019 | $43.71M | +14.2% |
| 2018 | $38.28M | +28.3% |
| 2017 | $29.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $68.99M | +8.4% | +10.9% |
| June 30, 2025 | $62.20M | +14.6% | -1.3% |
| March 31, 2025 | $63.03M | +19.6% | -0.9% |
| September 30, 2024 | $63.61M | +26.9% | +17.2% |
| June 30, 2024 | $54.29M | +39.7% | +3.0% |
| March 31, 2024 | $52.70M | +46.2% | +5.1% |
| September 30, 2023 | $50.13M | +67.4% | +29.0% |
| June 30, 2023 | $38.87M | +31.9% | +7.9% |
- Cogent Biosciences, Inc. showed an increase of +16.0% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Cogent Biosciences, Inc.’s r&d expense has grown by 804.3% (from $29.83 million to $269.78 million).
- The most recent figure is from Cogent Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: